Sat - Sun: Closed
Title Image

During the Second Quarter, Sales of PT. Pyridam Farma Tbk (PYFA) Up 147%

During the Second Quarter, Sales of PT. Pyridam Farma Tbk (PYFA) Up 147%

Jakarta, August 30, 2021 – PT. Pyridam Farma Tbk with the issuer name PYFA recorded sales of Rp. 105.1 billion in the second quarter of 2021, an increase of 147% compared to the second quarter of 2020. On a year-to-date basis, PYFA recorded net sales of Rp. 222.5 billion in its financial statements per year. June 30, 2021, an increase of 83% from the same period in 2020.

The increase in sales was driven by sales growth of pharmaceutical products, services, and tolls, which increased by 47% and sales growth of medical devices, which increased sharply by 725% or about 8 times from the previous year. The Company’s medical device segment continues to grow with a contribution of 24%, compared to 5% contribution in the same period in 2020. Meanwhile, the pharmaceutical, service, and tortilla products segment still dominates sales with a contribution of 76% of total sales.

The EBITDA obtained was Rp. 39.6 billion, 261% higher than the previous year, which was Rp. 10.97 billion. This increase was not only driven by sales growth, but also by cost efficiency. The ratio of operating expenses to net sales decreased from 58% in the first half of 2020 to 37% in the first half of 2021.

Director of PT. Pyridam Farma Tbk (PYFA), Yenfrino Gunadi said “Although it is still in a pandemic situation, thanks to careful planning and strategic steps PYFA managed to improve its performance better than the previous year. We will continue to actively explore opportunities for partnering to develop PYFA products and services for all Indonesians.”

At the end of the June 2021 book, the cash position of PT Pyridam Farma Tbk (PYFA) was at Rp 10.1 billion and total assets at Rp 578 billion. Meanwhile, total liabilities and total equity stood at Rp 403.4 billion and Rp 174.6 billion, respectively.

In the future, PT Pyridam Farma. Tbk (PYFA) is committed to continue to innovate and explore opportunities to establish strategic partnerships with various industries to advance the pharmaceutical industry in Indonesia, as well as to deliver products that meet the needs of the Indonesian people.

About PT Pyridam Farma Tbk.

PT Pyridam Farma Tbk is a pharmaceutical company whose main business is the production and/or distribution of modern and traditional medicines as well as the distribution of medical devices such as laboratory equipment as well as PCR test kits. The company was founded in 1976 and has been a public company and has been listed on the Indonesia Stock Exchange since 2001.

PT Pyridam Farma Tbk. manufactures a wide range of pharmaceutical products such as Antibiotics, Vitamins, Supplements, and Traditional Herbal Treatments. The company has more than 200 products in the form of tablets, caplets, capsules, cream syrups, and ointments. In addition, PT Pyridam Farma Tbk. also manufactures prescription products such as penicillin and non-penicillin antibiotics, and painkillers, as well as non-prescription products for vitamins, cold and cough suppressants, and antipyretics.